SLI-381 (Adderall XR)
McKeage K, Scott LJ.
Adis International Limited,
Mairangi Bay, Auckland, New Zealand.
CNS Drugs. 2003;17(9):669-75; . 2003 Jun;42(6):684-91
ABSTRACTSLI-381 is an extended-release formulation of short-acting Adderall, a racemic mixture of dextro- and levo-isomers of amphetamine salts. Drug-containing microbeads within the SLI-381 capsule give a double-pulsed delivery, similar to that achieved by two equal doses of the short-acting formulation administered 4 hours apart. In an intent-to-treat analysis of a 3-week, double-blind study in 563 children with attention-deficit hyperactivity disorder (ADHD), SLI-381 10, 20 or 30 mg once daily improved mean morning and afternoon behaviour scores compared with baseline significantly more than placebo (p < 0.001 for all comparisons), as assessed by the Connors Global Index Scale for teachers (CGIS-T). Following treatment, CGIS-T scores were similar to those reported in children without ADHD. In the same study, a dose-response relationship was observed, and increasing the dosage of SLI-381 by 10mg at weekly intervals, to a maximum of 30 mg once daily, resulted in further improvements in the scores of the CGIS-T. After early morning administration of SLI-381 in this double-blind study, late-afternoon scores of the CGIS for parents were similar to morning scores. SLI-381 was generally well tolerated in randomised trials in children with ADHD for up to 24 months. Overall, adverse events were mild to moderate in intensity.Adderall
Worms on speed
Kids on stimulants
Adderall in the classroom
Amphetamines for aphasics
Adderall versus methylphenidate
Amphetamine and the angry mouse
Food and drugs: Adderall v. Concerta for ADHD kids